This lymphoma represents a morphologically, genetically, and clinically heterogeneous entity and the detection of MYC-R associates with a poorer outcome after standard chemoimmunotherapy, as HGBL carrying MYC and BCL2 rearrangements [3, 5, 6]. The gene discussed is MYC; the disease is high grade B-cell lymphoma.